Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients

Background and study aims: Hereditary diffuse gastric cancer (HGGC), an autosomal dominant tumor-syndrome, accounts for 1 % to 3 % of gastric cancers worldwide. Presumably 30 % to 40 % of all patients fulfilling the clinical guidelines for HDGC are carriers of a pathogenic mutation in the CDH1 gene. Patients often show multiple foci of signet ring cell carcinoma at early age and are advised to undergo prophylactic total gastrectomy (PTG). Our aim was to improve the endoscopic detection of HDGC by using an enhanced endoscopic protocol.

Patient and methods: Patients with a proven CDH1 germline mutation identified in our institute were prospectively included. Patients were advised to undergo PTG and offered a baseline endoscopic examination prior surgery. Examination was performed by using high-resolution white-light endoscopy and pan-gastric chromoendoscopy with indigo carmine as dye combined with targeted and multiple random biopsies assessed by an expert histopathologist. Postoperative histopathology was compared with results from endoscopic biopsies.

Results: Between September 2012 and November 2014 8 patients with a proven CDH1 germline mutation were included. We conducted 44 targeted (6.3/patient) and 225 random (32.1/patient) biopsies in 7 patients. We detected 1 gastric cancer by random biopsy (14 %). All other examinations showed no signs of cancer.

Histopathology of gastrectomy specimen revealed multiple foci of gastric carcinoma in 6 patients (86 %) with a total number of 27 cancer foci.

Conclusions: Examination with targeted and random biopsies combined with chromoendoscopy is not able to detect small foci of gastric cancer in CDH1 mutation carriers. Therefore PTG is advocated in these patients.

^* Drs. Hüneburg and Marwitz contributed equally and Dr. Strassburg shared senior authorship with Dr. Nattermann.

• References

• 1 Palli D, Galli M, Caporaso NE et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiology Biomarkers & Prevention 1994; 3: 15-18
• 2 Henson DE, Dittus C, Younes M et al. Differential Trends in the Intestinal and Diffuse Types of Gastric Carcinoma in the United States, 1973–2000: Increase in the Signet Ring Cell Type. Archives of Pathology & Laboratory Medicine 2004; 128: 765-770
• 3 Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiologic reviews 1986; 8: 1-27
• 4 Jones EG. Familial Gastric Cancer. The New Zealand medical journal 1964; 63: 287-296
• 5 Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405
• 6 Hansford S, Kaurah P, Li-Chang H et al. Hereditary diffuse gastric cancer syndrome: Cdh1 mutations and beyond. JAMA Oncology 2015; 1: 23-32
• 7 Molinaro V, Pensotti V, Marabelli M et al. Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. Genes, chromosomes & cancer 2014; 53: 432-445
• 8 Oliveira C, Senz J, Kaurah P et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009; 18: 1545-1555
• 9 Chen Y, Kingham K, Ford JM et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Annals of surgical oncology 2011; 18: 2594-2598
• 10 Shaw D, Blair V, Framp A et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?. Gut 2005; 54: 461-468
• 11 Mayrbaeurl B, Keller G, Schauer W et al. Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members. European journal of gastroenterology & hepatology 2010; 22: 306-310
• 12 Keller G, Vogelsang H, Becker I et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. The American journal of pathology 1999; 155: 337-342
• 13 Gayther SA, Gorringe KL, Ramus SJ et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer research 1998; 58: 4086-4089
• 14 Guilford PJ, Hopkins JB, Grady WM et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Human mutation 1999; 14: 249-255
• 15 van der Post RS, Vogelaar IP, Carneiro F et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52: 361-374
• 16 Pharoah PD, Guilford P, Caldas C et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121: 1348-1353
• 17 Lynch HT, Kaurah P, Wirtzfeld D et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 2008; 112: 2655-2663
• 18 Pandalai PK, Lauwers GY, Chung DC et al. Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery 2011; 149: 347-355
• 19 Hebbard PC, Macmillan A, Huntsman D et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Annals of surgical oncology 2009; 16: 1890-1895
• 20 Seevaratnam R, Coburn N, Cardoso R et al. A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2012; 15 (Suppl. 01) 153-163
• 21 Lim YC, di Pietro M, O'Donovan M et al. Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointestinal endoscopy 2014; 80: 78-87
• 22 Dekker E, Boparai KS, Poley JW et al. High resolution endoscopy and the additional value of chromoendoscopy in the evaluation of duodenal adenomatosis in patients with familial adenomatous polyposis. Endoscopy 2009; 41: 666-669
• 23 Huneburg R, Lammert F, Rabe C et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009; 41: 316-322
• 24 Kahi CJ, Anderson JC, Waxman I et al. High-definition chromocolonoscopy vs.high-definition white light colonoscopy for average-risk colorectal cancer screening. The American journal of gastroenterology 2010; 105: 1301-1307
• 25 Fitzgerald RC, Hardwick R, Huntsman D et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47: 436-444
• 26 Frebourg T, Oliveira C, Hochain P et al. Cleft lip/palate and CDH1/E‐cadherin mutations in families with hereditary diffuse gastric cancer. Journal of Medical Genetics 2006; 43: 138-142
• 27 Choi JH, Kim ES, Lee YJ et al. Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer. Gastrointestinal endoscopy 2015; 82: 299-307
• 28 Rogers WM, Dobo E, Norton JA et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 2008; 32: 799-809
• 29 Fujita H, Lennerz JK, Chung DC et al. Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies. Am J Surg Pathol 2012; 36: 1709-1717
• 30 Kaurah P, MacMillan A, Boyd N et al. Founder and recurrent cdh1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297: 2360-2372
• 31 Newman EA, Mulholland MW. Prophylactic Gastrectomy for Hereditary Diffuse Gastric Cancer Syndrome. Journal of the American College of Surgeons 2006; 202: 612-617
• 32 Brettingham-Moore KH, Duong CP, Heriot AG et al. Using Gene Expression Profiling to Predict Response and Prognosis in Gastrointestinal Cancers – The Promise and the Perils. Annals of surgical oncology 2011; 18: 1484-1491
• 33 Chibon F. Cancer gene expression signatures – The rise and fall?. European journal of cancer 2013; 49: 2000-2009
• 34 Boussioutas A, Li H, Liu J et al. Distinctive Patterns of Gene Expression in Premalignant Gastric Mucosa and Gastric Cancer. Cancer Research 2003; 63: 2569-2577
• 35 Vecchi M, Nuciforo P, Romagnoli S et al. Gene expression analysis of early and advanced gastric cancers. Oncogene 2007; 26: 4284-4294
• 36 Nam S, Lee J, Goh S-H et al. Differential gene expression pattern in early gastric cancer by an integrative systematic approach. International Journal of Oncology 2012; 41: 1675-1682
• 37 Kim H, Eun JW, Lee H et al. Gene expression changes in patient-matched gastric normal mucosa, adenomas, and carcinomas. Experimental and Molecular Pathology 2011; 90: 201-209
• 38 Lee SK. Usefulness and Future Prospects of Confocal Laser Endomicroscopy for Gastric Premalignant and Malignant Lesions. Clin Endosc 2015; 48: 511-515
• 39 Lin X, Zhao Y, Song W-m et al. Molecular classification and prediction in gastric cancer. Computational and Structural Biotechnology Journal 2015; 13: 448-458